Literature DB >> 19349425

Bacillus anthracis edema toxin impairs neutrophil actin-based motility.

Sarah E Szarowicz1, Russell L During, Wei Li, Conrad P Quinn, Wei-Jen Tang, Frederick S Southwick.   

Abstract

Inhalation anthrax results in high-grade bacteremia and is accompanied by a delay in the rise of the peripheral polymorphonuclear neutrophil (PMN) count and a paucity of PMNs in the infected pleural fluid and mediastinum. Edema toxin (ET) is one of the major Bacillus anthracis virulence factors and consists of the adenylate cyclase edema factor (EF) and protective antigen (PA). Relatively low concentrations of ET (100 to 500 ng/ml of PA and EF) significantly impair human PMN chemokinesis, chemotaxis, and ability to polarize. These changes are accompanied by a reduction in chemoattractant-stimulated PMN actin assembly. ET also causes a significant decrease in Listeria monocytogenes intracellular actin-based motility within HeLa cells. These defects in actin assembly are accompanied by a >50-fold increase in intracellular cyclic AMP and a >4-fold increase in the phosphorylation of protein kinase A. We have previously shown that anthrax lethal toxin (LT) also impairs neutrophil actin-based motility (R. L. During, W. Li, B. Hao, J. M. Koenig, D. S. Stephens, C. P. Quinn, and F. S. Southwick, J. Infect. Dis. 192:837-845, 2005), and we now find that LT combined with ET causes an additive inhibition of PMN chemokinesis, polarization, chemotaxis, and FMLP (N-formyl-met-leu-phe)-induced actin assembly. We conclude that ET alone or combined with LT impairs PMN actin assembly, resulting in paralysis of PMN chemotaxis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349425      PMCID: PMC2687340          DOI: 10.1128/IAI.00839-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough.

Authors:  Sandriyana Soelaiman; Binqing Q Wei; Pamela Bergson; Young-Sam Lee; Yuequan Shen; Milan Mrksich; Brian K Shoichet; Wei-Jen Tang
Journal:  J Biol Chem       Date:  2003-04-03       Impact factor: 5.157

Review 2.  Integrin signaling to the actin cytoskeleton.

Authors:  Kris A DeMali; Krister Wennerberg; Keith Burridge
Journal:  Curr Opin Cell Biol       Date:  2003-10       Impact factor: 8.382

Review 3.  Bacterial invasion: the paradigms of enteroinvasive pathogens.

Authors:  Pascale Cossart; Philippe J Sansonetti
Journal:  Science       Date:  2004-04-09       Impact factor: 47.728

4.  Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src.

Authors:  V J Fincham; M James; M C Frame; S J Winder
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

5.  The vasodilator-stimulated phosphoprotein is regulated by cyclic GMP-dependent protein kinase during neutrophil spreading.

Authors:  D W Lawrence; K B Pryzwansky
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

6.  Active cAMP-dependent protein kinase incorporated within highly purified HIV-1 particles is required for viral infectivity and interacts with viral capsid protein.

Authors:  Christine Cartier; Bénédicte Hemonnot; Bernard Gay; Martine Bardy; Céline Sanchiz; Christian Devaux; Laurence Briant
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

Review 7.  Anthrax toxin.

Authors:  R John Collier; John A T Young
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

8.  Pathology and pathogenesis of bioterrorism-related inhalational anthrax.

Authors:  Jeannette Guarner; John A Jernigan; Wun-Ju Shieh; Kathleen Tatti; Lisa M Flannagan; David S Stephens; Tanja Popovic; David A Ashford; Bradley A Perkins; Sherif R Zaki
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

9.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

Authors:  J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more
  23 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

Review 2.  The adenylyl cyclase activity of anthrax edema factor.

Authors:  Wei-Jen Tang; Qing Guo
Journal:  Mol Aspects Med       Date:  2009-06-26

3.  Micropatterned macrophage analysis reveals global cytoskeleton constraints induced by Bacillus anthracis edema toxin.

Authors:  Yannick Trescos; Emilie Tessier; Clémence Rougeaux; Pierre L Goossens; Jean-Nicolas Tournier
Journal:  Infect Immun       Date:  2015-05-26       Impact factor: 3.441

Review 4.  Bacterial Virulence Factors: Secreted for Survival.

Authors:  Aditya Kumar Sharma; Neha Dhasmana; Neha Dubey; Nishant Kumar; Aakriti Gangwal; Meetu Gupta; Yogendra Singh
Journal:  Indian J Microbiol       Date:  2016-11-05       Impact factor: 2.461

5.  Glycogen synthase kinase 3 activation is important for anthrax edema toxin-induced dendritic cell maturation and anthrax toxin receptor 2 expression in macrophages.

Authors:  Jason L Larabee; Francisco J Maldonado-Arocho; Sergio Pacheco; Bryan France; Kevin DeGiusti; Salika M Shakir; Kenneth A Bradley; Jimmy D Ballard
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

6.  Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax.

Authors:  Fabien Dumetz; Grégory Jouvion; Huot Khun; Ian Justin Glomski; Jean-Philippe Corre; Clémence Rougeaux; Wei-Jen Tang; Michèle Mock; Michel Huerre; Pierre Louis Goossens
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

7.  Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.

Authors:  Eric K Dumas; Timothy Gross; Jason Larabee; Lance Pate; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Limone C Collins; Christina E Spooner; Hua Chen; Jimmy Ballard; Judith A James; A Darise Farris
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

8.  Potential role of autophagy in the bactericidal activity of human PMNs for Bacillus anthracis.

Authors:  Girish Ramachandran; Padmaja Gade; Pei Tsai; Wuyuan Lu; Dhananjaya V Kalvakolanu; Gerald M Rosen; Alan S Cross
Journal:  Pathog Dis       Date:  2015-09-30       Impact factor: 3.166

9.  Anthrax lethal and edema toxins fail to directly impair human platelet function.

Authors:  Kassidy M Chauncey; Sarah E Szarowicz; Gurjit S Sidhu; Russell L During; Frederick S Southwick
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

10.  A genome-wide survey for host response of silkworm, Bombyx mori during pathogen Bacillus bombyseptieus infection.

Authors:  Lulin Huang; Tingcai Cheng; Pingzhen Xu; Daojun Cheng; Ting Fang; Qingyou Xia
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.